Writing group disclosures

Writing group memberEmploymentResearch grantOther research supportSpeakers’ bureau/honorariaExpert witnessOwnership interestConsultant/advisory boardOther
Sarah D. de FerrantiBoston Children’s Heart FoundationNoneNoneNoneNoneNoneNoneNone
Robert H. EckelUniversity of Colorado Anschutz Medical CampusNoneNoneNoneNoneNoneNoneNone
Ian H. de BoerUniversity of WashingtonNoneNoneNoneNoneNoneNoneNone
Vivian FonsecaTulane University Health Sciences CenterAmerican Diabetes Association; Amylin; AstraZeneca; Daiichi Sankyo; Eli Lilly; MannKind; NIH; Novartis; Novo Nordisk; Sanofi; Takeda; DSMB member for NIH, Takeda, XomaNoneNoneConsultant for defense in legal proceedings involving Johnson & Johnson; consultant for defense in patent lawsuit involving Novo NordiskNoneAstraZeneca*; Daiichi Sankyo*; Daiichi Sumitomo*; Eli Lilly*; Merck; Novartis*; Novo Nordisk; Pan American Laboratories*; Sanofi; Santarus*None
Caroline S. FoxNIHNoneNoneNoneNoneNoneNoneAssociate Editor for Circulation*
Sherita Hill GoldenJohns Hopkins University School of MedicineNoneNoneNoneNoneNoneMerck & Co.*None
Carl J. LavieOchsner Health SystemNoneNoneNoneNoneNoneNoneNone
Sheela N. MaggeUniversity of Pennsylvania School of MedicineNoneNoneNoneNoneNoneNoneNone
Nikolaus MarxUniversity Hospital AachenBoehringer Ingelheim; GlaxoSmithKline; Medical Specialties Distributors; Novo NordiskNoneBoehringer Ingelheim; GlaxoSmithKline; Medical Specialties Distributors; Novo NordiskNoneNoneGlaxoSmithKline*; Medical Specialties Distributors*; Novo Nordisk*None
Darren K. McGuireUniversity of Texas Southwestern Medical Center at DallasBrigham and Women’s Hospital*; Cleveland Clinic Foundation*; Donald W. Reynolds Foundation; Eli Lilly*; Duke Clinical Research Institute*; Oxford University*; Saint Luke’s Health System*NoneNoneNoneNoneAstraZeneca; Daiichi Sankyo*; F. Hoffmann-La Roche*; Novo NordiskNone
Trevor J. OrchardUniversity of PittsburghNIH/NIDDK; DSMB member for CDC, NHLBI, NIDDKNoneNoneNoneNoneAstraZeneca*None
Bernard ZinmanMount Sinai Hospital/University of TorontoNoneNoneNoneNoneNoneNoneNone
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.